# Plain Language Summary: Biotechnology Oversight Coordination Act of 2024

Right now, different federal agencies handle biotechnology products separately—the Department of Agriculture oversees some things, the FDA handles others, and the Environmental Protection Agency manages different aspects. This bill creates a single coordinating committee to get all these agencies on the same page so they can work together more smoothly instead of making companies jump through hoops with multiple agencies doing overlapping reviews.

The bill establishes a new interagency committee led by the White House's Office of Science and Technology Policy that brings together representatives from the USDA, FDA, EPA, and other relevant agencies. The committee's main job is to streamline how biotechnology products get approved by aligning timelines, sharing information between agencies, and reducing duplicative reviews. For example, if a company develops a new genetically modified crop, instead of waiting for one agency to finish, then starting over with another, the agencies would coordinate so information flows smoothly and decisions happen faster. The committee also needs to identify a single point of contact for each type of biotech product so companies know exactly who to talk to first.

The bill requires the committee to report annually to Congress on what it's doing, including how long it takes to approve different types of biotech products and what barriers still exist. It also asks the committee to develop clearer standards for determining whether a biotech product could have occurred naturally or through conventional breeding, which would affect how strictly it gets regulated. The bill specifically excludes human medical research and drugs from this coordination effort—those continue to be handled solely by the FDA under existing rules. Essentially, this is about making the government's biotech approval process faster and more predictable while maintaining safety standards.